Följ
Seppo Meri
Seppo Meri
Verifierad e-postadress på helsinki.fi - Startsida
Titel
Citeras av
Citeras av
År
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
S Meri, BP Morgan, A Davies, RH Daniels, MG Olavesen, H Waldmann, ...
Immunology 71 (1), 1, 1990
6871990
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.
S Meri, MK Pangburn
Proceedings of the National Academy of Sciences 87 (10), 3982-3986, 1990
5291990
Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation
MK Liszewski, M Kolev, G Le Friec, M Leung, PG Bertram, AF Fara, ...
Immunity 39 (6), 1143-1157, 2013
5282013
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update
GB Appel, HT Cook, G Hageman, JC Jennette, M Kashgarian, ...
Journal of the American Society of Nephrology 16 (5), 1392-1403, 2005
5142005
The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi
J Hellwage, T Meri, T Heikkilä, A Alitalo, J Panelius, P Lahdenne, ...
Journal of Biological Chemistry 276 (11), 8427-8435, 2001
4692001
Complement activation after oxidative stress: role of the lectin complement pathway
CD Collard, A Väkevä, MA Morrissey, A Agah, SA Rollins, WR Reenstra, ...
The American journal of pathology 156 (5), 1549-1556, 2000
4642000
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome
T Manuelian, J Hellwage, S Meri, J Caprioli, M Noris, S Heinen, M Jozsi, ...
The Journal of clinical investigation 111 (8), 1181-1190, 2003
4062003
Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
A Harjunpää, S Junnikkala, S Meri
Scandinavian journal of immunology 51 (6), 634-641, 2000
3342000
The effects of type 2 diabetes mellitus on organ metabolism and the immune system
G Daryabor, MR Atashzar, D Kabelitz, S Meri, K Kalantar
Frontiers in immunology 11, 1582, 2020
3282020
New approaches to the treatment of dense deposit disease
RJH Smith, J Alexander, PN Barlow, M Botto, TL Cassavant, HT Cook, ...
Journal of the American Society of Nephrology 18 (9), 2447-2456, 2007
3272007
Molecular genetic characterization of the Fennoscandian cervid strain, a new genotypic group (G10) of Echinococcus granulosus
A Lavikainen, MJ Lehtinen, T Meri, V Hirvelä-Koski, S Meri
Parasitology 127 (3), 207-215, 2003
3202003
Factor H family proteins: on complement, microbes and human diseases
PF Zipfel, C Skerka, J Hellwage, ST Jokiranta, S Meri, V Brade, P Kraiczy, ...
Biochemical Society Transactions 30 (6), 971-978, 2002
3162002
Each of the three binding sites on complement factor H interacts with a distinct site on C3b
TS Jokiranta, J Hellwage, V Koistinen, PF Zipfel, S Meri
Journal of Biological Chemistry 275 (36), 27657-27662, 2000
3022000
Immune evasion of tumor cells using membrane-bound complement regulatory proteins
A Gorter, S Meri
Immunology today 20 (12), 576-582, 1999
3001999
Membrane proteins that protect against complement lysis
BP Morgan, S Meri
Springer seminars in immunopathology 15, 369-396, 1994
2981994
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein
M Laine, H Jarva, S Seitsonen, K Haapasalo, MJ Lehtinen, N Lindeman, ...
The Journal of Immunology 178 (6), 3831-3836, 2007
2922007
Dual interaction of factor H with C3d and glycosaminoglycans in host–nonhost discrimination by complement
T Kajander, MJ Lehtinen, S Hyvärinen, A Bhattacharjee, E Leung, ...
Proceedings of the National Academy of Sciences 108 (7), 2897-2902, 2011
2642011
Extended haplotypes in the complement factor H (CFH) and CFH‐related (CFHR) family of genes protect against age‐related macular degeneration …
GS Hageman, LS Hancox, AJ Taiber, KM Gehrs, DH Anderson, ...
Annals of medicine 38 (8), 592-604, 2006
2632006
The factor H protein family
PF Zipfel, TS Jokiranta, J Hellwage, V Koistinen, S Meri
Immunopharmacology 42 (1-3), 53-60, 1999
2601999
Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis.
S Meri, V Koistinen, A Miettinen, T Törnroth, IJ Seppälä
Journal of Experimental Medicine 175 (4), 939-950, 1992
2541992
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20